These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. McKenney JM; Sica D Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707 [TBL] [Abstract][Full Text] [Related]
4. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Backes J; Anzalone D; Hilleman D; Catini J Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154 [TBL] [Abstract][Full Text] [Related]
5. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Oscarsson J; Hurt-Camejo E Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250 [TBL] [Abstract][Full Text] [Related]
6. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204 [TBL] [Abstract][Full Text] [Related]
7. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story. Singh S; Arora RR; Singh M; Khosla S Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517 [TBL] [Abstract][Full Text] [Related]
8. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
9. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Preston Mason R Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567 [TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acids and cardiovascular disease: new developments and applications. Harris WS; Dayspring TD; Moran TJ Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766 [TBL] [Abstract][Full Text] [Related]
11. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. McKenney JM; Sica D Am J Health Syst Pharm; 2007 Mar; 64(6):595-605. PubMed ID: 17353568 [TBL] [Abstract][Full Text] [Related]
12. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690 [TBL] [Abstract][Full Text] [Related]
14. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides. Schwellenbach LJ; Olson KL; McConnell KJ; Stolcpart RS; Nash JD; Merenich JA; J Am Coll Nutr; 2006 Dec; 25(6):480-5. PubMed ID: 17229894 [TBL] [Abstract][Full Text] [Related]
15. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Orringer CE; Jacobson TA; Maki KC J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586 [TBL] [Abstract][Full Text] [Related]
16. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Picard F; Steg PG Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024 [TBL] [Abstract][Full Text] [Related]
18. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008 [TBL] [Abstract][Full Text] [Related]
19. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Weintraub H Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771 [TBL] [Abstract][Full Text] [Related]
20. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. Pirillo A; Catapano AL Int J Cardiol; 2013 Dec; 170(2 Suppl 1):S16-20. PubMed ID: 23856442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]